Learning-based dose prediction for pancreatic stereotactic body radiation therapy using dual pyramid adversarial network. (21st June 2021)

• Record Type: Journal Article
• Authors: Momin, Shadab; Lei, Yang; Wang, Tonghe; Zhang, Jiahan; Roper, Justin; Bradley, Jeffrey D; Curran, Walter J; Patel, Pretesh; Liu, Tian; Yang, Xiaofeng
• Is Part Of: Physics in medicine & biology. Volume 66:Number 12(2021)
• Publication Date: 2021-06-21
• Subjects: dose prediction -- deep learning -- SBRT -- pancreatic cancer; Biophysics -- Periodicals; Medical physics -- Periodicals; 610.153
• DOI: 10.1088/1361-6560/ac0856
• Languages: English
• ISSNs: 0031-9155

Abstract

Abstract: Treatment planning for pancreatic cancer stereotactic body radiation therapy (SBRT) is very challenging owing to vast spatial variations and close proximity of many organs-at-risk. Recently, deep learning (DL) based methods have been applied in dose prediction tasks of various treatment sites with the aim of relieving planning challenges. However, its effectiveness on pancreatic cancer SBRT is yet to be fully explored due to limited investigations in the literature. This study aims to further current knowledge in DL-based dose prediction tasks by implementing and demonstrating the feasibility of a new dual pyramid networks (DPNs) integrated DL model for predicting dose distributions of pancreatic SBRT. The proposed framework is composed of four parts: CT-only feature pyramid network (FPN), contour-only FPN, late fusion network and an adversarial network. During each phase of the network, combination of mean absolute error, gradient difference error, histogram matching, and adversarial loss is used for supervision. The performance of proposed model was demonstrated for pancreatic cancer SBRT plans with doses prescribed between 33 and 50 Gy across as many as three planning target volumes (PTVs) in five fractions. Five-fold cross validation was performed on 30 patients, and another 20 patients were used as holdout tests of trained model. Predicted plans were compared with clinically approved plans through dose volume parameters and two-paired t-test. For the same sets, our results were compared with three different DL architectures: 3D U-Net, 3D U-Net with adversarial learning, and DPN without adversarial learning. The proposed framework was able to predict 87% and 91% of clinically relevant dose parameters for cross validation sets and holdout sets, respectively, without any significant differences ( P > 0.05). Dose distribution predicted by our framework was also able to predict the intentional hotspots as feature characteristics of SBRT plans. Our method achieved higher correlation coefficients with the ground truth in 22/26, 24/26 and 20/26 dose volume parameters compared to the network without adversarial learning, 3D U-Net, and 3D U-Net with adversarial learning, respectively. Overall, the proposed model was able to predict doses to cases with both single and multiple PTVs. In conclusion, the DPN integrated DL model was successfully implemented, and demonstrated good dose prediction accuracy and dosimetric characteristics for pancreatic cancer SBRT.